temozolomide has been researched along with busulfan in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (9.09) | 29.6817 |
2010's | 9 (81.82) | 24.3611 |
2020's | 1 (9.09) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Anson, J; Gollard, RP; Khoury, J; Mason, J; Rosen, L | 1 |
Hupert, M; Linz, U; Santiago-Schübel, B; Stab, J; Wagner, S; Wien, S | 1 |
Armand, P; Batchelor, TT; Chen, YB; DeFilipp, Z; El-Jawahri, A; Li, S; Nayak, L; Wang, N | 1 |
Broome, AM; Jiang, YL | 1 |
Baehring, JM; Kaulen, LD | 1 |
2 review(s) available for temozolomide and busulfan
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Central Nervous System Neoplasms; Cranial Irradiation; Cyclophosphamide; Cytarabine; Humans; Immune Checkpoint Inhibitors; Lenalidomide; Lymphoma, Non-Hodgkin; Methotrexate; Nivolumab; Pemetrexed; Procarbazine; Prospective Studies; Receptors, Chimeric Antigen; Retrospective Studies; Rituximab; Temozolomide; Thiotepa; Vincristine | 2022 |
9 other study(ies) available for temozolomide and busulfan
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Intramedullary PNET of the spine: long-term survival after combined modality therapy and subsequent relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Female; Humans; Methylprednisolone Hemisuccinate; Neuroectodermal Tumors, Primitive; Neuroprotective Agents; Radiotherapy; Spinal Neoplasms; Temozolomide; Thiotepa; Thoracic Vertebrae; Vincristine; Young Adult | 2011 |
Transport of treosulfan and temozolomide across an in-vitro blood-brain barrier model.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Blood-Brain Barrier; Busulfan; Capillaries; Cells, Cultured; Dacarbazine; Endothelial Cells; Gray Matter; Swine; Temozolomide | 2015 |
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Methotrexate; Middle Aged; Mucositis; Remission Induction; Retrospective Studies; Rituximab; Stem Cell Transplantation; Temozolomide; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2017 |
Novel Pyrene Excimer and Fluorogenic Probe for the Detection of Alkylating Agents.
Topics: Alkylating Agents; Antineoplastic Agents; Busulfan; Chemical Warfare Agents; Fluorescent Dyes; Mustard Gas; Pipobroman; Pyrenes; Salicylates; Spectrometry, Fluorescence; Temozolomide | 2019 |